Atrial fibrillation

3 imperatives to transform health care in America. You're invited to watch it live

Free

E-newsletter

Subscribe to Housecall

Our weekly general interest
e-newsletter keeps you up to date on a wide variety of health topics.

Sign up now

Symptoms

By Mayo Clinic staff

Heart-Healthy Living

Subscribe to our Heart-Healthy Living e-newsletter to stay up to date on heart-health topics.

Sign up now

A heart in atrial fibrillation doesn't beat efficiently. It may not be able to pump enough blood out to your body with each heartbeat.

Some people with atrial fibrillation have no symptoms and are unaware of their condition until it's discovered during a physical examination. Those who do have atrial fibrillation symptoms may experience:

  • Palpitations, which are sensations of a racing, uncomfortable, irregular heartbeat or a flopping in your chest
  • Decreased blood pressure
  • Weakness
  • Lightheadedness
  • Confusion
  • Shortness of breath
  • Chest pain

Atrial fibrillation may be:

  • Occasional. In this case it's called paroxysmal (par-ok-SIZ-mul) atrial fibrillation. You may have symptoms that come and go, lasting for a few minutes to hours and then stopping on their own.
  • Chronic. With chronic atrial fibrillation, your heart rhythm is always abnormal.

When to see a doctor
If you have any symptoms of atrial fibrillation, make an appointment with your doctor. Your doctor should be able to tell you if your symptoms are caused by atrial fibrillation or another heart arrhythmia.

If you have chest pain, seek emergency medical assistance immediately. Chest pain could signal that you're having a heart attack.

References
  1. Atrial fibrillation (Afib). Heart Rhythm Society. http://www.hrsonline.org/Patient-Resources/Heart-Diseases-Disorders/Atrial-Fibrillation-AFib. Accessed Dec. 19, 2012.
  2. Atrial fibrillation. National Heart, Lung, and Blood Institute. http://www.nhlbi.nih.gov/health/health-topics/topics/af/. Accessed Dec. 19, 2012.
  3. Verdecchia P, et al. Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE intolerant subjects with cardiovascular disease studies. Journal of Hypertension. 2012;30:1004.
  4. Furie KL, et al. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: A science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43:3442.
  5. Pradaxa (prescribing information). Ridgefield, Conn.: Boehringer Ingelheim Pharmaceuticals; 2012. https://www.pradaxa.com/pradaxa-prescribing-information.jsp. Accessed Dec. 19, 2012.
  6. Cardioversion. National Heart, Lung, and Blood Institute. http://www.nhlbi.nih.gov/health/health-topics/topics/crv/. Accessed Dec. 19, 2012.
  7. Catheter ablation. National Heart, Lung, and Blood Institute. http://www.nhlbi.nih.gov/health/health-topics/topics/ablation/. Accessed Dec. 19, 2012.
  8. Cheng J, et al. Surgical approaches to prevent recurrent atrial fibrillation. http://www.uptodate.com/home. Accessed Dec. 19, 2012.
  9. Kumar K. Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations. http://www.uptodate.com/home. Accessed Dec. 19, 2012.
  10. Wann LS, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;57:223.
  11. Xarelto (prescribing information). Titusville, N.J.: Jansen Pharmaceuticals; 2012. http://www.xareltorems.com/rems/xarelto-prescribing-information.html. Accessed Dec. 19, 2012.
  12. How the heart works. National Heart, Lung, and Blood Institute. http://www.nhlbi.nih.gov/health/health-topics/topics/chd/heartworks.html. Accessed Dec. 19, 2012.
  13. FDA drug safety communication: Pradaxa (dabigatran etexilate mesylate) should not be used in patients with mechanical prosthetic heart valves. U.S. Food and Drug Administration. http://www.fda.gov/Drugs/DrugSafety/ucm332912.htm. Accessed Dec. 27, 2012.
DS00291 Feb. 8, 2013

© 1998-2013 Mayo Foundation for Medical Education and Research (MFMER). All rights reserved. A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.com," "EmbodyHealth," "Enhance your life," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.

  • Reprints
  • Print
  • Share on:

  • Email

Advertisement


Text Size: smaller largerlarger